Metrics to compare | 6887 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship6887PeersSector | |
|---|---|---|---|---|
P/E Ratio | −70.5x | −12.7x | −0.4x | |
PEG Ratio | 0.50 | −0.12 | 0.00 | |
Price/Book | 5.2x | 2.6x | 2.6x | |
Price / LTM Sales | 5.1x | 7.9x | 3.0x | |
Upside (Analyst Target) | - | 53.4% | 57.5% | |
Fair Value Upside | Unlock | −1.1% | 7.8% | Unlock |
Sunshine Lake Pharma Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products for the treatment of infectious diseases, chronic diseases, and oncology. It offers Kewei for the treatment of influenza; Dongweien and Dongyinghe for the treatment of hepatitis C. The company also engages in the import, export, wholesale, retail, and distribution of pharmaceutical products, intermediates, and active pharmaceutical ingredients; product quality inspection; research and development of biosimilar drugs and new biologic; research and production of generic drug; pharmaceutical information consultation, analysis and investigation and pharmaceutical market promotion; and research, development production, and sales of chemical raw material drugs and chemical preparations. The company was formerly known as Sunshine Lake Pharma Ltd. The company was established in 2001 and is based in Dongguan, China.